Literature DB >> 32094254

Immune Profile of the Nasal Mucosa in Patients with Cutaneous Leishmaniasis.

María J Gómez-Zafra1,2, Adriana Navas2,3, Jimena Jojoa2,3, Julieth Murillo2,4, Camila González1, María Adelaida Gómez5,3.   

Abstract

Localized skin lesions are characteristic of cutaneous leishmaniasis (CL); however, Leishmania (Viannia) species, which are responsible for most CL cases in the Americas, can spread systemically, sometimes resulting in mucosal disease. Detection of Leishmania has been documented in healthy mucosal tissues (conjunctiva, tonsils, and nasal mucosa) and healthy skin of CL patients and in individuals with asymptomatic infection in areas of endemicity of L (V) panamensis and L (V) braziliensis transmission. However, the conditions and mechanisms that favor parasite persistence in healthy mucosal tissues are unknown. In this descriptive study, we compared the cell populations of the nasal mucosa (NM) of healthy donors and patients with active CL and explored the immune gene expression signatures related to molecular detection of Leishmania in this tissue in the absence of clinical signs or symptoms of mucosal disease. The cellular composition and gene expression profiles of NM samples from active CL patients were similar to those of healthy volunteers, with a predominance of epithelial over immune cells, and within the CD45+ cell population, a higher frequency of CD66b+ followed by CD14+ and CD3+ cells. In CL patients with molecular evidence of Leishmania persistence in the NM, genes characteristic of an anti-inflammatory and tissue repair responses (IL4R, IL5RA, POSTN, and SATB1) were overexpressed relative to NM samples from CL patients in which Leishmania was not detected. Here, we report the first immunological description of subclinically infected NM tissues of CL patients and provide evidence of a local anti-inflammatory environment favoring parasite persistence in the NM.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Th1/Th2; asymptomatic infection; cutaneous leishmaniasis; nasal mucosa; persistence

Mesh:

Substances:

Year:  2020        PMID: 32094254      PMCID: PMC7171237          DOI: 10.1128/IAI.00881-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  54 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 2.  Leishmaniasis in immunosuppressed individuals.

Authors:  J van Griensven; E Carrillo; R López-Vélez; L Lynen; J Moreno
Journal:  Clin Microbiol Infect       Date:  2014-02-20       Impact factor: 8.067

3.  Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.

Authors:  Annette Ives; Catherine Ronet; Florence Prevel; Giulia Ruzzante; Silvia Fuertes-Marraco; Frederic Schutz; Haroun Zangger; Melanie Revaz-Breton; Lon-Fye Lye; Suzanne M Hickerson; Stephen M Beverley; Hans Acha-Orbea; Pascal Launois; Nicolas Fasel; Slavica Masina
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

4.  Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Authors:  Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prével; Chantal Desponds; Daniel T Utzschneider; Dietmar Zehn; Maria G Cusi; F Matthew Kuhlmann; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

5.  Heterogeneity, geographic distribution, and pathogenicity of serodemes of Leishmania viannia in Colombia.

Authors:  Nancy Gore Saravia; Kristen Weigle; Claudia Navas; Iris Segura; Liliana Valderrama; Anais Zully Valencia; Blanca Escorcia; Diane McMahon-Pratt
Journal:  Am J Trop Med Hyg       Date:  2002-06       Impact factor: 2.345

6.  Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?

Authors:  Mitzi G Mendonça; Maria E F de Brito; Eduardo H G Rodrigues; Valdir Bandeira; Márcio L Jardim; Frederico G C Abath
Journal:  J Infect Dis       Date:  2004-03-02       Impact factor: 5.226

7.  Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure.

Authors:  A Schubach; M C Marzochi; T Cuzzi-Maya; A V Oliveira; M L Araujo; A L Oliveira; R S Pacheco; H Momen; F Conceicao-Silva; S G Coutinho; K B Marzochi
Journal:  Am J Trop Med Hyg       Date:  1998-06       Impact factor: 2.345

8.  Live attenuated influenza virus (LAIV) induces different mucosal T cell function in nonsmokers and smokers.

Authors:  Katherine M Horvath; Luisa E Brighton; Margaret Herbst; Terry L Noah; Ilona Jaspers
Journal:  Clin Immunol       Date:  2012-01-06       Impact factor: 3.969

9.  Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared to Nasal Wash.

Authors:  Simon P Jochems; Katherine Piddock; Jamie Rylance; Hugh Adler; Beatriz F Carniel; Andrea Collins; Jenna F Gritzfeld; Carole Hancock; Helen Hill; Jesus Reiné; Alexandra Seddon; Carla Solórzano; Syba Sunny; Ashleigh Trimble; Angela D Wright; Seher Zaidi; Stephen B Gordon; Daniela M Ferreira
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

10.  Respiratory viral infection in the chronic persistent phase of chronic rhinosinusitis.

Authors:  Bo Liao; Chun-Yan Hu; Tao Liu; Zheng Liu
Journal:  Laryngoscope       Date:  2013-10-02       Impact factor: 3.325

View more
  1 in total

1.  The level of interleukin-17, 23, and gamma interferon in cutaneous leishmaniasis patients before and after intra lesion treatment.

Authors:  Mehdi Ghazanfari; Bahador Shahriari; Vahid Rahnama; Meisam Khazaei; Shahrbanou Naderi; Mohammad Hossein Motazedian
Journal:  J Parasit Dis       Date:  2022-02-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.